ClinicalTrials.gg
CompletedNCT00703326Updated Dec 6, 2021Results posted

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

A Phase 3 interventional study of ramucirumab (IMC-1121B) and docetaxel in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 233 sites in 23 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,144
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
4th of 80
1,144 · median 138
Started
2008
with 2 others
Phase 3
16 of 88
1 open now
Registered
37th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 4th largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2008, is one of 16 in phase 3, and was the 37th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.

Read the detailed description

Female participants at least 18 years of age with histologically or cytologically confirmed, human epidermal growth factor receptor 2 (HER2) negative breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent will be randomized. Participants may not have received chemotherapy for metastatic or locally-recurrent, inoperable breast cancer.

It is anticipated that 1113 participants will be randomized with 371 participants in the docetaxel plus placebo arm and 742 participants in the docetaxel plus ramucirumab (IMC-1121B) arm. There will be approximately 250 centers in North and South America, Europe, Asia, Middle East, Africa, Australia, and New Zealand.

On Day 1 of each 21-day cycle, participants will receive docetaxel 75 mg/m² as a one-hour I.V. infusion followed by either ramucirumab (IMC-1121B) 10 mg/kg or placebo 10 mg/kg as a one-hour I.V. infusion. Each cycle is repeated every 21 days.

Treatment will continue until there is evidence of progressive disease, unacceptable toxicity, or other withdrawal criteria are met. Participants who discontinue study treatment with either ramucirumab (IMC-1121B) or placebo may continue to receive docetaxel.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Metastatic breast cancer
  • HER2 negative breast cancer
  • locally recurrent breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is able to provide signed
  • Participant is female and ≥ 18 years of age or older if required by local laws or regulations
  • Participant has or cytologically confirmed adenocarcinoma of the breast that is now or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic or surgical specimen available for confirmation of diagnosis
  • Participant has measurable and/or non-
  • Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 ()-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)
  • Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer
  • Participant completed (neo) taxane therapy at least 6 months prior to randomization
  • Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization
  • Participant completed all prior radiotherapy with curative intent ≥ 3 weeks prior to randomization
  • Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting ≥ 2 weeks prior to randomization
  • Participant's is within normal institutional ranges
  • Participant has resolution to grade ≤ 1 by the National Cancer Institute , Version 3 (NCI-CTCAE v 3.0) of all toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade ≤ 2
  • Participant has an (ECOG) performance status of 0-1
  • Participant is amenable to compliance with protocol schedules and testing
  • Participant has adequate hematological functions [ (ANC) ≥ 1500 cells/microliter (mcL), ≥ 9 grams/deciliter (g/dL), and ≥ 100,000 cells/mcL and ≤ 850,000 cells/mcL]
  • Participant has adequate hepatic function [ within normal limits (WNL), (AST) and alanine transaminase (ALT) ≤ 2.5 times the (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ≤ 5.0 times the ULN]
  • Participant has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated should be > 40 milliliters/minute (mL/min)
  • Participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA); if urine protein ≥ 2+, a 24-hour urine collection must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study
  • Participant must have adequate coagulation function as defined by (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)
  • Women of must implement adequate in the opinion of the investigator
  • Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer

Exclusion criteria

Exclusion Criteria:

  • Participant has a concurrent active other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years
  • Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80
  • Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)
  • Participant has a history of chronic diarrheal disease within 6 months prior to randomization
  • Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization
  • Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization
  • Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  • Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization
  • Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
  • Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • Participant has , uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or
  • Participant has known infection or acquired immunodeficiency syndrome-related illness
  • Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
  • Participant is pregnant or lactating
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,144 participants (actual)

Study arms

  • Experimental
    ramucirumab (IMC-1121B) + docetaxel

    Biological: ramucirumab (IMC-1121B) · Drug: docetaxel

  • Placebo comparator
    placebo + docetaxel

    Drug: docetaxel · Other: Placebo

Interventions

  • Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

    Also known as: IMC-1121B, LY3009806

  • Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

  • OtherPlacebo

    Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after ≥2 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression.

    Time frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the duration from randomization to death from any cause. Participants who were alive at data cut-off for the OS analysis or lost to follow-up were censored on the last date the participant was known to be alive.

    Time frame: Randomization to death or until data cutoff of 29-May-2015 (up to 82 months)

  2. Time to Progression (TTP)

    TTP was defined as the time from the date of randomization to the first documented date of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who did not progress were censored at the last radiographic tumor assessment. If no post-baseline assessment was available censoring occurred at the date of randomization. If PD occurred after 2 or more missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression.

    Time frame: Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 56 months)

  3. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate)

    Objective response rate (ORR) was defined as the percentage of randomized participants achieving a best confirmed overall response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), based on the achievement of both measurement and confirmation criteria; by Investigator assessment. CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions, taking as reference the baseline sum LD and no progression in non-target lesions.

    Time frame: Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 56 months)

  4. Duration of Response

    Duration of complete response (CR) or partial response (PR) measured from time criteria were first met for CR or PR until first date of progressive disease (PD) or death from any cause defined using Response Evaluation Criteria in Solid Tumor (RECIST 1.0); by Investigator assessment. CR defined as disappearance of all target and non-target lesions. PR defined as ≥30% decrease in sum of longest diameter (LD) of target lesions and no progression in non-target lesions. PD defined as ≥20% increase in LD sum of target lesions taking as reference the smallest sum LD since baseline, progression in non-target lesions or the appearance of ≥1 new lesion(s). Participants who did not relapse or die censored at day of last radiographic tumor assessment. If death or PD was after ≥2 missing radiographic visits, censoring was at date of last radiographic visit prior to missed visits. Symptomatic/clinical disease progression without documented radiologic progression did not constitute progression.

    Time frame: Date of first CR or PR to PD or death or until data cutoff date of 31-Mar-2013 (up to 56 months)

  5. Total Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy

    FACT-B measures the following domains of health-related quality of life (HR-QoL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and additional concerns of breast cancer subscale (BCS) each with 6 or more items developed to measure problems specific to breast cancer symptoms plus additional items related to global QoL. Participants respond to each of the 36 questions on a 5-point scale from 0 (not at all) to 4 (very much) with a total scores range of 0-144. Higher scores indicate fewer symptoms and better HR-QoL.

    Time frame: Baseline, End of Therapy or until data cutoff of 31-Mar-2013 (up to 56 months)

  6. Number of Participants With Adverse Events

    Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and other NSAEs is located in the Reported Adverse Event module.

    Time frame: First dose to study completion (up to 12.3 years)

  7. Immunogenicity: Percentage of Participants With Treatment Emergent Anti-Ramucirumab Antibodies Until Primary Data Cutoff of 31-Mar-2013

    Percentage of participants with treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies during the study. Participants were considered positive for anti-ramucirumab (IMC-1121B) antibodies if they exhibited a post-treatment antibody level that exceeded the positive upper cut point determined from the anti-ramucirumab (IMC-1121B) level seen in healthy untreated individuals.

    Time frame: Baseline, prior to cycle 3 infusion, prior to cycle 5 infusion, onset of infusion reaction, resolution of reaction and 30 days following the event up to 56 months

  8. Immunogenicity: Percentage of Participants Available After 31-Mar-2013 With Treatment Emergent Anti-Ramucirumab Antibodies Until Data Cutoff From 01-Apr-2013 to 08-Sep-2016

    Percentage of participants with treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies during the study. Participants were considered positive for anti-ramucirumab (IMC-1121B) antibodies if they exhibited a post-treatment antibody level that exceeded the positive upper cut point determined from the anti-ramucirumab (IMC-1121B) level seen in healthy untreated individuals.

    Time frame: Follow-up from 01-Apr-2013 to 08-Sep-2016 (Up to 56 -97 months)

07

Results

Posted Jun 17, 2014
Limitations and caveats
One participant assigned to placebo + docetaxel (doc) treatment and was given ramucirumab (ram) in Cycle 1. Considered ram + doc treatment arm for safety population, for ITT population the participant was analyzed according to assigned treatment.

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Started759385
Received at least 1 dose of study drug752382
Completed657347
Not completed10238
Withdrew: Lost to follow-up4718
Withdrew: Withdrawal by subject5420
Withdrew: Adverse event10

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after ≥2 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression.

Time frame:
Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Progression-Free Survival (PFS)9.5 (8.3 to 9.8)8.2 (7.1 to 8.5)
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · Stratified Log Rank (SLR) · p = 0.077 · Hazard ratio (hr): 0.88 · 95% CI 0.75 to 1.01HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors.
SecondaryOverall Survival (OS)

OS was defined as the duration from randomization to death from any cause. Participants who were alive at data cut-off for the OS analysis or lost to follow-up were censored on the last date the participant was known to be alive.

Time frame:
Randomization to death or until data cutoff of 29-May-2015 (up to 82 months)
Reported as:
Median · months
Overall Survival (OS)
monthsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Overall Survival (OS)30.3 (27.5 to 33.5)28.7 (25.6 to 32.3)
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · Stratified Log Rank (SLR) · p = 0.487 (The gate-keeping strategy used to control overall type 1 error 0.05 (2-sided) or 0.025 (1-sided) to analyze progression-free survival (PFS) and OS. At final PFS analysis only if primary PFS test was significant would analysis of OS be inferential.) · Hazard ratio (hr): 0.95 · 95% CI 0.81 to 1.10HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors.
SecondaryTime to Progression (TTP)

TTP was defined as the time from the date of randomization to the first documented date of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who did not progress were censored at the last radiographic tumor assessment. If no post-baseline assessment was available censoring occurred at the date of randomization. If PD occurred after 2 or more missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression.

Time frame:
Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 56 months)
Reported as:
Median · months
Time to Progression (TTP)
monthsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Time to Progression (TTP)9.7 (8.5 to 10.3)8.2 (7.1 to 9.0)
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · Stratified Log Rank (SLR) · p = 0.033 · Hazard ratio (hr): 0.85 · 95% CI 0.73 to 0.99HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors.
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate)

Objective response rate (ORR) was defined as the percentage of randomized participants achieving a best confirmed overall response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), based on the achievement of both measurement and confirmation criteria; by Investigator assessment. CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions, taking as reference the baseline sum LD and no progression in non-target lesions.

Time frame:
Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 56 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate)
percentage of participantsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate)44.7 (41.1 to 48.3)37.9 (33.1 to 43.0)
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · Stratified Cochran-Mantel-Haenszel(SCMH) · p = 0.027 · Odds ratio (or): 1.33 · 95% CI 1.03 to 1.71Stratified odds ratio was calculated considering the IWRS stratification factors.
SecondaryDuration of Response

Duration of complete response (CR) or partial response (PR) measured from time criteria were first met for CR or PR until first date of progressive disease (PD) or death from any cause defined using Response Evaluation Criteria in Solid Tumor (RECIST 1.0); by Investigator assessment. CR defined as disappearance of all target and non-target lesions. PR defined as ≥30% decrease in sum of longest diameter (LD) of target lesions and no progression in non-target lesions. PD defined as ≥20% increase in LD sum of target lesions taking as reference the smallest sum LD since baseline, progression in non-target lesions or the appearance of ≥1 new lesion(s). Participants who did not relapse or die censored at day of last radiographic tumor assessment. If death or PD was after ≥2 missing radiographic visits, censoring was at date of last radiographic visit prior to missed visits. Symptomatic/clinical disease progression without documented radiologic progression did not constitute progression.

Time frame:
Date of first CR or PR to PD or death or until data cutoff date of 31-Mar-2013 (up to 56 months)
Reported as:
Median · months
Duration of Response
monthsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Duration of Response8.4 (8.0 to 9.7)8.1 (6.8 to 8.9)
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · Stratified Log Rank (SLR) · p = 0.150 · Hazard ratio (hr): 0.84 · 95% CI 0.67 to 1.06HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors.
SecondaryTotal Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy

FACT-B measures the following domains of health-related quality of life (HR-QoL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and additional concerns of breast cancer subscale (BCS) each with 6 or more items developed to measure problems specific to breast cancer symptoms plus additional items related to global QoL. Participants respond to each of the 36 questions on a 5-point scale from 0 (not at all) to 4 (very much) with a total scores range of 0-144. Higher scores indicate fewer symptoms and better HR-QoL.

Time frame:
Baseline, End of Therapy or until data cutoff of 31-Mar-2013 (up to 56 months)
Reported as:
Mean · units on a scale
Total Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy
units on a scaleRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Total Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy-6.8 ± 17.3-7.0 ± 16.8
Statistical analysis
  • Ramucirumab (IMC-1121B) + Docetaxel vs Placebo + Docetaxel · ANCOVA · p = 0.539 (P-value is for end of therapy. Analysis of covariance (ANCOVA) adjusted for baseline score was used to compare the 2 treatment arms.)
SecondaryNumber of Participants With Adverse Events

Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and other NSAEs is located in the Reported Adverse Event module.

Time frame:
First dose to study completion (up to 12.3 years)
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Participants with SAEs285117
Participants with NSAEs737373
SecondaryImmunogenicity: Percentage of Participants With Treatment Emergent Anti-Ramucirumab Antibodies Until Primary Data Cutoff of 31-Mar-2013

Percentage of participants with treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies during the study. Participants were considered positive for anti-ramucirumab (IMC-1121B) antibodies if they exhibited a post-treatment antibody level that exceeded the positive upper cut point determined from the anti-ramucirumab (IMC-1121B) level seen in healthy untreated individuals.

Time frame:
Baseline, prior to cycle 3 infusion, prior to cycle 5 infusion, onset of infusion reaction, resolution of reaction and 30 days following the event up to 56 months
Reported as:
Number · percentage of participants
Immunogenicity: Percentage of Participants With Treatment Emergent Anti-Ramucirumab Antibodies Until Primary Data Cutoff of 31-Mar-2013
percentage of participantsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Immunogenicity: Percentage of Participants With Treatment Emergent Anti-Ramucirumab Antibodies Until Primary Data Cutoff of 31-Mar-20130.80.8
SecondaryImmunogenicity: Percentage of Participants Available After 31-Mar-2013 With Treatment Emergent Anti-Ramucirumab Antibodies Until Data Cutoff From 01-Apr-2013 to 08-Sep-2016

Percentage of participants with treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies during the study. Participants were considered positive for anti-ramucirumab (IMC-1121B) antibodies if they exhibited a post-treatment antibody level that exceeded the positive upper cut point determined from the anti-ramucirumab (IMC-1121B) level seen in healthy untreated individuals.

Time frame:
Follow-up from 01-Apr-2013 to 08-Sep-2016 (Up to 56 -97 months)
Reported as:
Number · percentage of participants
Immunogenicity: Percentage of Participants Available After 31-Mar-2013 With Treatment Emergent Anti-Ramucirumab Antibodies Until Data Cutoff From 01-Apr-2013 to 08-Sep-2016
percentage of participantsRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Immunogenicity: Percentage of Participants Available After 31-Mar-2013 With Treatment Emergent Anti-Ramucirumab Antibodies Until Data Cutoff From 01-Apr-2013 to 08-Sep-201600

Adverse events

Collected over First dose to study completion (up to 12.3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab (IMC-1121B) + Docetaxel—285/752 (37.9%)737/752 (98%)
Placebo + Docetaxel—117/382 (30.6%)373/382 (97.6%)
Most frequent serious events
Showing 10 of 246
Most frequent serious events
EventRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders51/75211/382
NeutropeniaBlood and lymphatic system disorders47/75220/382
UnderdoseInjury, poisoning and procedural complications11/75212/382
Neutropenic infectionInfections and infestations19/7529/382
PneumoniaInfections and infestations15/7525/382
Pleural effusionRespiratory, thoracic and mediastinal disorders8/7526/382
FatigueGeneral disorders10/7521/382
OverdoseInjury, poisoning and procedural complications7/7525/382
DyspnoeaRespiratory, thoracic and mediastinal disorders5/7525/382
DiarrhoeaGastrointestinal disorders9/7522/382
Most frequent other events
Showing 10 of 61
Most frequent other events
EventRamucirumab (IMC-1121B) + DocetaxelPlacebo + Docetaxel
AlopeciaSkin and subcutaneous tissue disorders535/752279/382
StomatitisGastrointestinal disorders380/752118/382
DiarrhoeaGastrointestinal disorders326/752152/382
NauseaGastrointestinal disorders278/752156/382
EpistaxisRespiratory, thoracic and mediastinal disorders300/75264/382
FatigueGeneral disorders271/752135/382
AstheniaGeneral disorders270/752127/382
Lacrimation increasedEye disorders233/75265/382
Nail disorderSkin and subcutaneous tissue disorders231/752105/382
HypertensionVascular disorders204/75244/382

Baseline characteristics

Intent-to-Treat (ITT) Population: All randomized participants.

Age, Categorical
Age, Categorical(Participants)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
<=18 years000
Between 18 and 65 years629325954
>=65 years13060190
Age, Continuous
Age, Continuous(years)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
Mean53.9 ± 10.554.2 ± 10.054.0 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
Female7593851144
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
Hispanic or Latino6942111
Not Hispanic or Latino6903431033
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
American Indian or Alaska Native112
Asian312051
Native Hawaiian or Other Pacific Islander202
Black or African American271441
White6763411017
More than one race000
Unknown or Not Reported22931
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab (IMC-1121B) + DocetaxelPlacebo + DocetaxelTotal
Serbia022
United States582179
Taiwan426
Slovakia224
Spain11864182
Lebanon241438
Ireland8210
Russia21099309
Israel16723
United Kingdom211031
Egypt9312
Czechia437
Canada8346129
Poland12517
Belgium482068
Brazil302050
Peru12416
Australia282149
South Africa412263
Germany12517
New Zealand5611
South Korea14721
08

Study locations

233 sites
  • ImClone Investigational Site
    Birmingham, Alabama 35202, United States
  • ImClone Investigational Site
    Mobile, Alabama 36608, United States
  • ImClone Investigational Site
    Chandler, Arizona 85224, United States
  • ImClone Investigational Site
    Gilbert, Arizona 85297, United States
  • ImClone Investigational Site
    Mesa, Arizona 85206, United States
  • ImClone Investigational Site
    Alhambra, California 91801, United States
  • ImClone Investigational Site
    Bakersfield, California 93309, United States
  • ImClone Investigational Site
    Chula Vista, California 91911, United States
  • ImClone Investigational Site
    La Mesa, California 91942, United States
  • ImClone Investigational Site
    Los Angeles, California 90095, United States
  • ImClone Investigational Site
    Oceanside, California 92056, United States
  • ImClone Investigational Site
    Pasadena, California 01107, United States
  • ImClone Investigational Site
    Pasadena, California 91105, United States
  • ImClone Investigational Site
    San Diego, California 92123, United States
  • ImClone Investigational Site
    Santa Barbara, California 93105, United States
  • ImClone Investigational Site
    Santa Maria, California 93454, United States
  • ImClone Investigational Site
    Santa Monica, California 90404, United States
  • ImClone Investigational Site
    Solvang, California 93463, United States
  • ImClone Investigational Site
    Valencia, California 91355, United States
  • ImClone Investigational Site
    Aurora, Colorado 80045, United States
  • ImClone Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • ImClone Investigational Site
    Gainesville, Florida 32605, United States
  • ImClone Investigational Site
    New Port Richey, Florida 34655, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30341, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30342, United States
  • ImClone Investigational Site
    Macon, Georgia 31217, United States
  • ImClone Investigational Site
    Marietta, Georgia 30060, United States
  • ImClone Investigational Site
    Alton, Illinois 62002, United States
  • ImClone Investigational Site
    Chicago, Illinois 60076, United States
  • ImClone Investigational Site
    Chicago, Illinois 60611, United States
  • ImClone Investigational Site
    Skokie, Illinois 60076, United States
  • ImClone Investigational Site
    Elkhart, Indiana 46514, United States
  • ImClone Investigational Site
    Mishawaka, Indiana 46545, United States
  • ImClone Investigational Site
    South Bend, Indiana 46601, United States
  • ImClone Investigational Site
    Westville, Indiana 46891, United States
  • ImClone Investigational Site
    Lexington, Kentucky 40604, United States
  • ImClone Investigational Site
    Lansing, Michigan 48912, United States
  • ImClone Investigational Site
    Saint Joseph, Michigan 49085, United States
  • ImClone Investigational Site
    Minneapolis, Minnesota 55415, United States
  • ImClone Investigational Site
    Southaven, Mississippi 38671, United States
  • ImClone Investigational Site
    Saint Louis, Missouri 63136, United States
  • ImClone Investigational Site
    Grand Island, Nebraska 68803, United States
  • ImClone Investigational Site
    Kearney, Nebraska 68845, United States
  • ImClone Investigational Site
    Henderson, Nevada 89052, United States
  • ImClone Investigational Site
    New York, New York 10011, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 15830, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 28203, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 28210, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 28211, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 28262, United States
  • ImClone Investigational Site
    Charlotte, North Carolina 28294, United States
  • ImClone Investigational Site
    Bismarck, North Dakota 58501, United States
  • ImClone Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • ImClone Investigational Site
    Portland, Oregon 97239, United States
  • ImClone Investigational Site
    West Reading, Pennsylvania 19611, United States
  • ImClone Investigational Site
    Bartlett, Tennessee 38133, United States
  • ImClone Investigational Site
    Germantown, Tennessee 38138, United States
  • ImClone Investigational Site
    Memphis, Tennessee 38104, United States
  • ImClone Investigational Site
    Memphis, Tennessee 38119, United States
  • ImClone Investigational Site
    Memphis, Tennessee 38120, United States
  • ImClone Investigational Site
    Niles, Tennessee 49120, United States
  • ImClone Investigational Site
    Oxford, Tennessee 38655, United States
  • ImClone Investigational Site
    Lubbock, Texas 79410, United States
  • ImClone Investigational Site
    Temple, Texas 76508, United States
  • ImClone Investigational Site
    Salt Lake City, Utah 84106, United States
  • ImClone Investigational Site
    Fitzroy, Victoria 3065, Australia
  • ImClone Investigational Site
    Frankston, Victoria 3199, Australia
  • ImClone Investigational Site
    Bankstown, NSW2200, Australia
  • ImClone Investigational Site
    Bedford Park, SA 5042, Australia
  • ImClone Investigational Site
    Box Hill, V1C 3128, Australia
  • ImClone Investigational Site
    Darlinghurst, NSW 2010, Australia
  • ImClone Investigational Site
    East Bentleigh, VIC 3165, Australia
  • ImClone Investigational Site
    East Melbourne, 3002, Australia
  • ImClone Investigational Site
    Herston, QLD 4029, Australia
  • ImClone Investigational Site
    Hobart, 7000, Australia
  • ImClone Investigational Site
    Milton, QLD 4064, Australia
  • ImClone Investigational Site
    Nambour, QLD 4560, Australia
  • ImClone Investigational Site
    New Lambton Heights, NSW 2305, Australia
  • ImClone Investigational Site
    Perth, WA 6001, Australia
  • ImClone Investigational Site
    Ringwood East, 3135, Australia
  • ImClone Investigational Site
    Subiaco, 6008, Australia
  • ImClone Investigational Site
    Sydney, NSW 2010, Australia
  • ImClone Investigational Site
    Tweed Heads, NSW 2305, Australia
  • ImClone Investigational Site
    Wendouree, VIC 3355, Australia
  • ImClone Investigational Site
    Brasschaat, 2930, Belgium
  • ImClone Investigational Site
    Charleroi, 6000, Belgium
  • ImClone Investigational Site
    Edegem, 2650, Belgium
  • ImClone Investigational Site
    Gent, 9000, Belgium
  • ImClone Investigational Site
    Kortrijk, 8500, Belgium
  • ImClone Investigational Site
    Liege, 4000, Belgium
  • ImClone Investigational Site
    Namur, 5000, Belgium
  • ImClone Investigational Site
    Yvoir, 5530, Belgium
  • ImClone Investigational Site
    Ijui, 98700-000, Brazil
  • ImClone Investigational Site
    Porto Alegre, 90035-001, Brazil
  • ImClone Investigational Site
    Porto Alegre, 90430-090, Brazil
  • ImClone Investigational Site
    Porto Alegre, 906-000, Brazil
  • ImClone Investigational Site
    Rio de Janeiro, 21941-913, Brazil
  • ImClone Investigational Site
    San Paulo, 05651-901, Brazil
  • ImClone Investigational Site
    San Paulo, 1246-000, Brazil
  • ImClone Investigational Site
    Santo Andre, 09060-650, Brazil

Showing the first 100 of 233 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Dec 1;28(12):2932-2942. doi: 10.1093/annonc/mdx514. PubMed 28950290 ↗
  • Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017 Aug 1;28(8):1836-1841. doi: 10.1093/annonc/mdx264. PubMed 28520849 ↗
  • Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2015 Jan 10;33(2):141-8. doi: 10.1200/JCO.2014.57.1513. Epub 2014 Sep 2. PubMed 25185099 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2008 to primary completion in Mar 2013, 55 months.

Results were first posted in Jun 2014, 1 year 2 months after primary completion. A results delay was requested in Jul 2010.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 55 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2008
First posted
Jun 23, 2008
StartActual
Aug 6, 2008
Primary completionActual
Mar 31, 2013
CompletionActual
Nov 19, 2020
Results delay requested
Jul 29, 2010
Results first posted
Jun 17, 2014
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00703326
Responsible party
Sponsor
First posted
Jun 23, 2008
Start date
Aug 6, 2008
Primary completion
Mar 31, 2013
Completion
Nov 19, 2020
Results posted
Jun 17, 2014
Last update
Dec 6, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion